A Study of Secukinumab for the Treatment of Alopecia Areata

Phase 2

Terminated

Conditions: Alopecia Areata

Interventions: Drug: Placebo
Drug: Secukinumab

Registration Number: NCT02599129

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Brief Summary: Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body.

Alopecia areata is an autoimmune skin disease, which means that the immune system is recognizing the hair follicles as foreign and attacking them, causing round patches of hair loss. It can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis). The scalp is the most commonly affected area, but the beard or any hair-bearing site can be affected alone or together with the scalp. Alopecia areata occurs in males and females of all ages, and is a highly unpredictable condition that tends to recur. Alopecia areata can cause significant distress to both patients and their families.

Aim: To assess the effects of a new treatment called secukinumab in patients with alopecia areata. A total of 30 patients will be included in the study, which will run for a total of 28 weeks.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 11

Inclusion Criteria

Male or female subject at least 18 years of age
If female, the subject is not pregnant or nursing
Subject is able to provide written informed consent and comply with the requirements of this study protocol.
Subjects who are women of childbearing potential must have a negative urine pregnancy test at screening and must be practicing an adequate, medically acceptable method of birth control for at least 30 days before Day 0 and at least 6 months after the last study drug administration. Acceptable methods of birth control include intrauterine device (IUD); oral, transdermal, implanted or injected hormonal contraceptives (must have been initiated at least 1 month before entering the study); tubal ligation; abstinence and barrier methods with spermicide. Otherwise, if not of childbearing potential, subjects must: have a sterile or vasectomized partner; have had a hysterectomy, a bilateral oophorectomy or be clinically diagnosed infertile; or be in a menopausal state for at least a year.
Subject with AA (unequivocal cases of AA), affecting at least 60% of the scalp, and present for at least 6 months.
Tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT) negative at the time of screening, or if patient has a history of positive PPD or QuantiFERON, he/she has completed the appropriate prophylaxis.
Subject is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, and physical examination.

Exclusion Criteria

Other concomitant types of alopecia (androgenetic, female pattern, traction, scarring and others)
Any subject who is pregnant or refuses to practice an acceptable method of birth control (as stated in inclusion criterion # 4)
History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection as defined by a positive tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT) at screening. Subjects with a positive or indeterminate PPD or QFT test may participate in the study if a full tuberculosis work up (according to local practice/guidelines) is completed within 12 weeks prior to randomization and establishes conclusively that the subject has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment must have been initiated at least for 4 weeks prior to randomization and the course of prophylaxis is planned to be completed.
Active Crohn's disease
Known hypersensitivity to latex
Subjects with a history of HIV, or history of positive HCV or HBV
Previous exposure to Secukinumab or other drug targeting IL-17A or its receptor; use of sensitizing therapy for alopecia areata including DPCP, squaric acid, DNCB within 1 month; PUVA, or any form of phototherapy within 1 month; use of any immunosuppressive therapies (systemic corticosteroids, methotrexate, azathioprine, mycophenolate mofetil, cyclosporine) within 1 month; or use of topical therapies (two weeks). All the above therapies will not be allowed during this study.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	matching placebo subcutaneous injections
Secukinumab	Secukinumab	300 mg subcutaneous injections

Primary Outcome Measures

Name	Time	Method
Number of Subjects Achieving Severity of Alopecia Tool (SALT) Score of 50	Week 24	Number of subjects achieving a Severity of Alopecia Tool (SALT) score of 50 at Week 24

Secondary Outcome Measures

Name	Time	Method
Number of Subjects Achieving a SALT Score of 90 at Week 24	week 24	We assessed the Number of subjects that achieved a SALT score of 90 at week 24
Number of Subjects With Dermatology Life Quality Index (DLQI) of 3 or Above	Week 24	Number of subjects achieving a DLQI (Dermatology Life Quality Index), patient global assessment score of 3 or above at week 24 (0, no regrowth; 1, \<25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth).
Number of Subjects Achieving a SALT Score of 90 at Week 28	week 28	We assessed the Number of subjects that achieved a SALT score of 90 at Week 28
Number of Subjects Acheiving Physician's Global Assessment (PGA) Score of 3 or Above	Week 24	Number of subjects achieving a Physician's Global Assessment (PGA) score of 3 or above at week 24 (0, no regrowth; 1, \<25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth).